000299497 001__ 299497
000299497 005__ 20250228163923.0
000299497 0247_ $$2doi$$a10.1016/j.canep.2025.102782
000299497 0247_ $$2pmid$$apmid:40015231
000299497 0247_ $$2ISSN$$a1877-7821
000299497 0247_ $$2ISSN$$a1877-783X
000299497 037__ $$aDKFZ-2025-00456
000299497 041__ $$aEnglish
000299497 082__ $$a610
000299497 1001_ $$aMuhammad, Noor$$b0
000299497 245__ $$aAnticipation effect in Pakistani breast cancer families with or without BRCA1/2 pathogenic variants.
000299497 260__ $$aAmsterdam [u.a.]$$bElsevier$$c2025
000299497 3367_ $$2DRIVER$$aarticle
000299497 3367_ $$2DataCite$$aOutput Types/Journal article
000299497 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1740749730_25618
000299497 3367_ $$2BibTeX$$aARTICLE
000299497 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000299497 3367_ $$00$$2EndNote$$aJournal Article
000299497 520__ $$aGenetic anticipation refers to the earlier onset of breast cancer (BC) in successive generations, is underreported in Asian populations. This study investigates the phenomenon in Pakistani familial BC patients.The study analyzed 171 mother-daughter BC pairs, including BRCA1 (n = 52), BRCA2 (n = 11) pathogenic variant (PV) carriers, and non-carriers (n = 108). Additionally, 741 first-degree female relatives of the mothers and daughters, affected (n = 96) or unaffected (n = 645) with BC, were included. Ages at BC diagnosis in mother-daughter pairs were compared using a paired t-test, while differences in BC occurrence between daughters' and mothers' generations were assessed using odds ratios (ORs).Daughters were diagnosed with BC significantly earlier than their mothers, with intergenerational age differences of 14.3 years in BRCA1 (33.7 vs. 48.0; P < 0.0001), 11.5 years in BRCA2 (37.4 vs. 48.9; P < 0.0001) PV carriers, and 12.6 years in non-carriers (41.3 vs. 53.9; P < 0.0001). This difference was independent of birth cohort effects and ascertainment bias. While BC incidence was 20 % higher in the mothers' generation compared to the daughters' generation (42.7 % vs. 38.3 %; OR 1.20, 95 % CI 0.94 - 1.53; P = 0.135), the difference was not statistically significant. Survival durations between generations were also comparable (4.49 years vs. 3.94 years; P = 0.465).This first study on anticipation effect in Pakistani familial BC patients demonstrates significantly earlier BC onset in daughters than in mothers, irrespective of BRCA1/2 PV carrier status. These findings highlight the need to refine BC screening guidelines for high-risk Pakistani populations.
000299497 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000299497 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000299497 650_7 $$2Other$$aBRCA1/2 pathogenic variants
000299497 650_7 $$2Other$$aBreast cancer
000299497 650_7 $$2Other$$aGenetic anticipation
000299497 650_7 $$2Other$$aMother-daughter pairs
000299497 650_7 $$2Other$$aPakistan
000299497 7001_ $$aNaeemi, Humaira$$b1
000299497 7001_ $$aArif, Shumaila$$b2
000299497 7001_ $$0P:(DE-He78)537e07b3e57b16c7b214fc2242e4326b$$aHamann, Ute$$b3
000299497 7001_ $$aRashid, Muhammad Usman$$b4
000299497 773__ $$0PERI:(DE-600)2498032-8$$a10.1016/j.canep.2025.102782$$gVol. 96, p. 102782 -$$p102782$$tCancer epidemiology$$v96$$x1877-7821$$y2025
000299497 909CO $$ooai:inrepo02.dkfz.de:299497$$pVDB
000299497 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)537e07b3e57b16c7b214fc2242e4326b$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000299497 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000299497 9141_ $$y2025
000299497 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER EPIDEMIOL : 2022$$d2024-12-16
000299497 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-16
000299497 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-16
000299497 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-16
000299497 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-16
000299497 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-16
000299497 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-16
000299497 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-16
000299497 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-16
000299497 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-16
000299497 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-16
000299497 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-16
000299497 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-16
000299497 9201_ $$0I:(DE-He78)B072-20160331$$kB072$$lMolekulargenetik des Mammakarzinoms$$x0
000299497 980__ $$ajournal
000299497 980__ $$aVDB
000299497 980__ $$aI:(DE-He78)B072-20160331
000299497 980__ $$aUNRESTRICTED